Not all IGHV3-21 chronic lymphocytic leukemias are equal: Prognostic considerations

Panagiotis Baliakas, Andreas Agathangelidis, Anastasia Hadzidimitriou, Lesley Ann Sutton, Eva Minga, Athina Tsanousa, Lydia Scarfò, Zadie Davis, Xiao Jie Yan, Tait Shanafelt, Karla Plevova, Yorick Sandberg, Fie Juhl Vojdeman, Myriam Boudjogra, Tatiana Tzenou, Maria Chatzouli, Charles C. Chu, Silvio Veronese, Anne Gardiner, Larry MansouriKarin E. Smedby, Lone Bredo Pedersen, Denis Moreno, Kirsten Van Lom, Véronique Giudicelli, Hana Skuhrova Francova, Florence Nguyen-Khac, Panagiotis Panagiotidis, Gunnar Juliusson, Lefteris Angelis, Achilles Anagnostopoulos, Marie Paule Lefranc, Monica Facco, Livio Trentin, Mark Catherwood, Marco Montillo, Christian H. Geisler, Anton W. Langerak, Sarka Pospisilova, Nicholas Chiorazzi, David Oscier, Diane F. Jelinek, Nikos Darzentas, Chrysoula Belessi, Frederic Davi, Paolo Ghia, Richard Rosenquist, Kostas Stamatopoulos

Research output: Contribution to journalArticlepeer-review

47 Scopus citations


An unresolved issue in chronic lymphocytic leukemia (CLL) is whether IGHV3-21 gene usage, in general, or the expression of stereotyped B-cell receptor immunoglobulin defining subset #2 (IGHV3-21/IGLV3-21), in particular, determines outcome for IGHV3-21-utilizing cases. We reappraised this issue in 8593 CLL patients of whom 437 (5%) used the IGHV3-21 gene with 254/437 (58%) classified as subset #2.Within subset #2, immunoglobulin heavy variable (IGHV)-mutated cases predominated, whereas non-subset #2/IGHV3-21 was enriched for IGHV-unmutated cases (P = .002). Subset #2 exhibited significantly shorter time-to-first-treatment (TTFT) compared with non-subset #2/IGHV3-21 (22 vs 60 months, P = .001). No such difference was observed between non-subset #2/IGHV3-21 vs the remaining CLL with similar IGHV mutational status. In conclusion, IGHV3-21 CLL should not be axiomatically considered a homogeneous entity with adverse prognosis, given that only subset #2 emerges as uniformly aggressive, contrasting non-subset #2/IGVH3-21 patients whose prognosis depends on IGHV mutational status as the remaining CLL.

Original languageEnglish (US)
Pages (from-to)856-859
Number of pages4
Issue number5
StatePublished - Jan 29 2015

ASJC Scopus subject areas

  • Biochemistry
  • Immunology
  • Hematology
  • Cell Biology


Dive into the research topics of 'Not all IGHV3-21 chronic lymphocytic leukemias are equal: Prognostic considerations'. Together they form a unique fingerprint.

Cite this